IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v45y2022i8d10.1007_s40264-022-01200-4.html
   My bibliography  Save this article

A Disproportionality Analysis of Drug–Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)

Author

Listed:
  • Lorenzo Villa-Zapata

    (Mercer University)

  • Ainhoa Gómez-Lumbreras

    (University of Utah)

  • John Horn

    (University of Washington)

  • Malinda S. Tan

    (University of Utah)

  • Richard D. Boyce

    (University of Pittsburgh)

  • Daniel C. Malone

    (University of Utah)

Abstract

Introduction Tizanidine is primarily metabolized via cytochrome P450 (CYP) 1A2 and therefore medications that inhibit the enzyme will affect the clearance of tizanidine, leading to increased plasma concentrations of tizanidine and potentially serious adverse events. Objectives Our aim was to study the occurrence of adverse events reported in the FDA Adverse Event Reporting System (FAERS) involving the combination of tizanidine and drugs that inhibit the metabolic activity of CYP1A2. Methods A disproportionality analysis of FAERS reports from 2004 quarter 1 through 2020 quarter 3 was conducted to calculate the reporting odds ratio (ROR) of reports mentioning tizanidine in a suspect or interacting role or having any role, a CYP1A2 inhibitor, and the following adverse events: hypotension, bradycardia, syncope, shock, cardiorespiratory arrest, and fall or fracture. Results A total of 89 reports were identified mentioning tizanidine, at least one CYP1A2 inhibitor, and one of the adverse events of interest. More than half of the reports identified tizanidine as having a suspect or interacting role (n = 59, 66.3%), and the reports more frequently involved women (n = 58, 65.1%). The median age was 56.1 years (standard deviation 17.1). Some of the important safety signals included interactions between tizanidine in a suspect or interacting role and ciprofloxacin (ROR for hypotension 28.1, 95% confidence interval [CI] 19.2–41.2) or fluvoxamine (ROR for hypotension 36.9, 95% CI 13.1–103.4), and also when reported in “any role” with ciprofloxacin (ROR for hypotension 6.3, 95% CI 4.7–8.5), fluvoxamine (ROR for hypotension 11.4, 95% CI 4.5–28.8), and zafirlukast (ROR for falls 16.0, 95% CI 6.1–42.1). Conclusions Reports involving tizanidine and a CYP1A2 inhibitor have higher odds of reporting hypotension. This study suggests that concurrent use of tizanidine with CYP1A2 inhibitors may lead to serious health consequences associated with low blood pressure such as falls and fractures.

Suggested Citation

  • Lorenzo Villa-Zapata & Ainhoa Gómez-Lumbreras & John Horn & Malinda S. Tan & Richard D. Boyce & Daniel C. Malone, 2022. "A Disproportionality Analysis of Drug–Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)," Drug Safety, Springer, vol. 45(8), pages 863-871, August.
  • Handle: RePEc:spr:drugsa:v:45:y:2022:i:8:d:10.1007_s40264-022-01200-4
    DOI: 10.1007/s40264-022-01200-4
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-022-01200-4
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40264-022-01200-4?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:45:y:2022:i:8:d:10.1007_s40264-022-01200-4. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.